Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rebecca Leonard

Showing results (31-40 of 33) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 33 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 19, 2022
Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction CorrelatesEvan C Chen, Helen Gandler, Isidora Tošić, et al.
Blood Advances|December 5, 2023
Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemiaAndrew A Lane, Jacqueline S Garcia, Evangeline G Raulston, et al.
Blood|January 27, 2023
Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid diseaseLivius Penter, Yang Liu, Jacquelyn O Wolff, et al.
Pageof 4

Showing results (31-40 of 33) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 33 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 19, 2022
Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction CorrelatesEvan C Chen, Helen Gandler, Isidora Tošić, et al.
Blood Advances|December 5, 2023
Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemiaAndrew A Lane, Jacqueline S Garcia, Evangeline G Raulston, et al.
Blood|January 27, 2023
Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid diseaseLivius Penter, Yang Liu, Jacquelyn O Wolff, et al.
Pageof 4